Valuation Myriad Genetics, Inc.
Equities
MYGN
US62855J1043
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.210 USD | -1.23% |
|
+1.69% | -47.41% |
| Nov. 26 | Sector Update: Health Care Stocks Edge Higher Premarket Wednesday | MT |
| Nov. 25 | Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment | MT |
Company Valuation: Myriad Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,487 | 2,204 | 1,176 | 1,697 | 1,248 | 672.1 | - | - |
| Change | - | 48.19% | -46.65% | 44.34% | -26.46% | -46.15% | - | - |
| Enterprise Value (EV) 1 | 1,595 | 1,864 | 1,061 | 1,595 | 1,185 | 651.8 | 650.3 | 646.2 |
| Change | - | 16.87% | -43.09% | 50.32% | -25.67% | -45.01% | -0.24% | -0.63% |
| P/E ratio | -6.42x | -78.9x | -10.4x | -6.02x | -9.72x | -1.77x | -10.4x | -13.4x |
| PBR | 1.69x | 2.28x | 1.33x | 2.2x | 1.79x | 1.83x | 1.9x | 1.9x |
| PEG | - | 0.9x | -0x | -0x | 0.2x | -0x | 0.1x | 0.6x |
| Capitalization / Revenue | 2.67x | 3.19x | 1.73x | 2.25x | 1.49x | 0.82x | 0.78x | 0.73x |
| EV / Revenue | 2.86x | 2.7x | 1.56x | 2.12x | 1.42x | 0.79x | 0.75x | 0.71x |
| EV / EBITDA | - | 25.9x | -50.5x | -253x | 29.3x | 20.9x | 17.6x | 13.7x |
| EV / EBIT | -20.5x | 205x | -32.3x | -62.5x | 54.4x | 85.1x | 52.2x | 32x |
| EV / FCF | -24.7x | 11.5x | -7x | -9.16x | -42.8x | -21.2x | -151x | 57.2x |
| FCF Yield | -4.05% | 8.7% | -14.3% | -10.9% | -2.34% | -4.73% | -0.66% | 1.75% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.08 | -0.35 | -1.39 | -3.18 | -1.41 | -4.072 | -0.6925 | -0.54 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 557 | 690.6 | 678.4 | 753.2 | 837.6 | 822.1 | 866.7 | 915.5 |
| EBITDA 1 | - | 71.9 | -21 | -6.3 | 40.4 | 31.14 | 36.95 | 47.13 |
| EBIT 1 | -77.9 | 9.1 | -32.8 | -25.5 | 21.8 | 7.66 | 12.46 | 20.21 |
| Net income 1 | - | -27.2 | -112 | -263.3 | -127.3 | -378.6 | -66.49 | -52.55 |
| Net Debt 1 | 107.8 | -339.8 | -114.9 | -102.4 | -62.8 | -20.25 | -21.79 | -25.87 |
| Reference price 2 | 19.775 | 27.600 | 14.510 | 19.140 | 13.710 | 7.210 | 7.210 | 7.210 |
| Nbr of stocks (in thousands) | 75,210 | 79,855 | 81,034 | 88,669 | 91,035 | 93,214 | - | - |
| Announcement Date | 2/23/21 | 2/24/22 | 2/28/23 | 2/27/24 | 2/24/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.77x | 0.79x | 20.94x | -.--% | 672M | |
| 27.23x | 3.01x | 12.35x | 0.85% | 14.84B | |
| -33.07x | 14.16x | -65.01x | -.--% | 13.15B | |
| -20.91x | 9.86x | 113.58x | - | 7.55B | |
| 27.2x | 9.47x | 21.79x | 2.05% | 6.49B | |
| 20.07x | 3.05x | 8.27x | - | 4.42B | |
| 18.48x | 3.26x | 9.85x | 1.86% | 4.03B | |
| 17.07x | - | - | 3.5% | 2.87B | |
| Average | 6.79x | 6.23x | 17.40x | 1.38% | 6.75B | |
| Weighted average by Cap. | 3.68x | 7.70x | 8.17x | 1.03% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MYGN Stock
- Valuation Myriad Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
